Printer Friendly

Dr. Reddy's sells API manufacturing unit to Therapiva.

Dr. Reddy's Laboratories announced that it has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private Ltd., an emerging generics pharmaceutical company. This divestiture is being done by way of slump sale and includes all related fixed assets, current assets, current liabilities, and its employees. "The divestiture of our API manufacturing business unit is a step towards streamlining our manufacturing operations and optimizing our cost structures," said Sanjay Sharma, Executive Vice President & Head, Global Manufacturing Operations. "We are confident that we have found in Therapiva, a buyer-partner who fully understands and appreciates the business unit and its people as a powerful strategic asset." Therapiva Private Limited is a joint venture between Omnicare Drugs India Private Limited and Laxai Life Sciences Private Ltd.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Oct 15, 2018
Words:134
Previous Article:KBRwyle awarded $48M contract to build NextGen NASA SG SLR.
Next Article:Infrastructure and Energy Alternatives to acquire William Charles Construction.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters